Aspergillosis
Itraconazole for chronic pulmonary aspergillosis: Longer is better
A randomized controlled trial in India demonstrated that 12 months of oral itraconazole was superior to a 6-month regimen in reducing relapses of chronic pulmonary aspergillosis, researchers reported in The Lancet Infectious Diseases.
‘New entity’ of COVID-19-associated aspergillosis linked to poor outcomes
Patients with COVID-19-associated pulmonary aspergillosis, or CAPA, experience worse outcomes than COVID-19 patients who do not have the fungal infection, according to study results published in Clinical Infectious Diseases.
Influenza-associated aspergillosis is uncommon in US, study shows
Influenza-associated aspergillosis, or IAA, is uncommon in ICU patients in the United States, with a prevalence of 0.3%, according to an analysis of health insurance claims data.
Most Americans unaware of major fungal diseases, survey finds
Nearly 70% of adults in the United States have never heard of six major fungal diseases, according to results from a first-of-its-kind survey published in MMWR.
Hospital aspergillosis deaths decrease from 2001-2011
SAN DIEGO — In-hospital deaths and the length of stay among aspergillosis patients in the United States decreased from 2001-2011, recent data suggest.